Clinical trial readout dates for Veradermics Incorporated, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
| Phase 3 VDPHL01 Androgenetic Alopecia; AGA · NCT06972264 | December 2026 Ongoing |
| Phase 3 VDPHL01 QD Androgenetic Alopecia (AGA); Androgenetic Alopecia · NCT07146022 | June 2027 Ongoing |
Veradermics Incorporated reported $798M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-10). Its net loss for that quarter was $21M; at that rate the cash would last about 38 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-10 |
| 8-K Other Events — often topline trial data | 2026-11-09 |